BRPI0812340A2 - Macrociclos e seus usos - Google Patents

Macrociclos e seus usos

Info

Publication number
BRPI0812340A2
BRPI0812340A2 BRPI0812340-3A2A BRPI0812340A BRPI0812340A2 BR PI0812340 A2 BRPI0812340 A2 BR PI0812340A2 BR PI0812340 A BRPI0812340 A BR PI0812340A BR PI0812340 A2 BRPI0812340 A2 BR PI0812340A2
Authority
BR
Brazil
Prior art keywords
macrocycles
Prior art date
Application number
BRPI0812340-3A2A
Other languages
English (en)
Inventor
Roger Aki Fujimoto
Philipp Krastel
Matthew J Lamarche
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0812340A2 publication Critical patent/BRPI0812340A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0812340-3A2A 2007-06-04 2008-06-03 Macrociclos e seus usos BRPI0812340A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94177707P 2007-06-04 2007-06-04
PCT/EP2008/056838 WO2008148754A2 (en) 2007-06-04 2008-06-03 Macrocycles and their uses

Publications (1)

Publication Number Publication Date
BRPI0812340A2 true BRPI0812340A2 (pt) 2015-01-27

Family

ID=40094226

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812340-3A2A BRPI0812340A2 (pt) 2007-06-04 2008-06-03 Macrociclos e seus usos

Country Status (24)

Country Link
US (2) US8476224B2 (pt)
EP (1) EP2170907A2 (pt)
JP (1) JP2010529076A (pt)
KR (1) KR101202483B1 (pt)
CN (1) CN101772506B (pt)
AR (1) AR066865A1 (pt)
AU (1) AU2008258639B2 (pt)
BR (1) BRPI0812340A2 (pt)
CA (1) CA2688621A1 (pt)
CL (1) CL2008001613A1 (pt)
CO (1) CO6270222A2 (pt)
CR (1) CR11158A (pt)
EA (1) EA200901613A1 (pt)
EC (1) ECSP099836A (pt)
GT (1) GT200900310A (pt)
IL (1) IL202285A0 (pt)
MA (1) MA31562B1 (pt)
MX (1) MX2009013214A (pt)
NZ (1) NZ581917A (pt)
PE (1) PE20090318A1 (pt)
TN (1) TN2009000495A1 (pt)
TW (1) TW200902540A (pt)
WO (1) WO2008148754A2 (pt)
ZA (1) ZA200908262B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708793C (en) 2007-12-12 2016-06-21 Novartis Ag Aminothiazoles and their uses
WO2018073269A1 (en) * 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
CN109485617B (zh) * 2018-12-11 2023-01-31 贵州永诺菲特生物制药有限公司 一种n-甲基-2-异丙基-4-噻唑甲胺的制备方法
WO2024044751A2 (en) * 2022-08-26 2024-02-29 Wake Forest University Health Sciences Peroxiredoxin 3 inhibitors and methods of use for treating cancer
WO2025038747A1 (en) * 2023-08-14 2025-02-20 Rs Oncology, Llc Modified thiostrepton-inspired compounds for treatment of cancer and preparation thereof
TW202613105A (zh) * 2024-06-21 2026-04-01 美商Ｒｓ腫瘤學有限責任公司 用於治療癌症之經修飾之硫鏈絲菌肽啟發之化合物及其製備

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0451486T3 (da) 1990-03-08 1995-05-08 Lepetit Spa Antibiotikum GE 2270 faktorer B1, B2, C1, C2, D1, D2, E og T
DE4011378A1 (de) 1990-04-07 1991-10-10 Hausen Auto Kabel Gmbh & Co Kg Anschlussklemme fuer akkumulator oder dergleichen
IL100572A (en) 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
DE69224497T2 (de) 1991-08-30 1998-07-02 Biosearch Italia Spa Faktor C2a des Antibiotikums CE 2270
EP0880541B1 (en) * 1996-02-14 2003-01-15 Biosearch Italia S.p.A. Derivatives of antibiotic ge2270 factors
JPH1059997A (ja) * 1996-08-22 1998-03-03 Microbial Chem Res Found アミチアマイシンアミド誘導体
DK1553967T3 (da) * 2002-06-17 2011-08-29 Naicons S C A R L Anvendelse af et amidderivat af GE 2270 faktor A3 til behandling af acne
US20050106159A1 (en) * 2003-08-12 2005-05-19 Thompson Stuart A. Campylobacter jejuni outer membrane protein immunogenic composition
PE20080103A1 (es) 2006-05-31 2008-04-03 Novartis Ag AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
WO2008082562A2 (en) 2006-12-20 2008-07-10 Novartis Ag Aminothiazole macrocycles, their use as antibacterial compounds and processes for their production

Also Published As

Publication number Publication date
GT200900310A (es) 2010-05-21
AR066865A1 (es) 2009-09-16
US8476224B2 (en) 2013-07-02
TN2009000495A1 (en) 2011-03-31
PE20090318A1 (es) 2009-04-17
IL202285A0 (en) 2010-06-16
US8691756B2 (en) 2014-04-08
EA200901613A1 (ru) 2010-06-30
US20130252883A1 (en) 2013-09-26
ZA200908262B (en) 2010-08-25
TW200902540A (en) 2009-01-16
WO2008148754A2 (en) 2008-12-11
WO2008148754A3 (en) 2009-03-05
KR20100021496A (ko) 2010-02-24
CR11158A (es) 2010-01-20
MX2009013214A (es) 2010-01-15
CA2688621A1 (en) 2008-12-11
NZ581917A (en) 2011-04-29
MA31562B1 (fr) 2010-08-02
AU2008258639A1 (en) 2008-12-11
ECSP099836A (es) 2010-01-29
AU2008258639B2 (en) 2012-07-05
JP2010529076A (ja) 2010-08-26
KR101202483B1 (ko) 2012-11-16
EP2170907A2 (en) 2010-04-07
CN101772506A (zh) 2010-07-07
CL2008001613A1 (es) 2009-05-15
CN101772506B (zh) 2014-02-12
US20090186830A1 (en) 2009-07-23
CO6270222A2 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
BRPI0817881A2 (pt) Compostos orgânicos e seus usos
BRPI0813244A2 (pt) Compostos e seus usos 708
BRPI1016150A2 (pt) compostos heterocíclicos e seus usos.
BRPI0908853A2 (pt) composto oligopeptídicos e seus usos
BRPI0710878A2 (pt) Compostos orgânicos e seus usos
BRPI0910746A2 (pt) reticuladores e seus usos
BRPI0921862A2 (pt) inibidores de raf e seus usos
BRPI0909185A2 (pt) Derivado de vitamina e e seus usos
BRPI0808098A2 (pt) 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
BR112012000660A2 (pt) compostos heterociclos e seus usos
BRPI0913640A2 (pt) substâncias policrômicas e seus usos
BRPI0816165A2 (pt) Dispositivo de citaferese seletiva e seus métodos relacionados
BRPI0810172A2 (pt) Polipeptídeos de fator vii modificado e seus usos
BRPI0817685A2 (pt) Polissacarídeos com funcionalidade azetidínio e seus usos
BR112012004802A2 (pt) polipeptídeos tendo atividade oxirredutase e seus usos
PT2473527T (pt) Formulações estáveis de polipéptidos e seus usos
BRPI0912284A2 (pt) Polímeros antimicrobianos e seus usos
BRPI0809103A2 (pt) composições de magnésio e seus usos
EP2111835A4 (en) VOIDABLE ARTICLE
BRPI0913885A2 (pt) Tiadiazoliloxifenilamidinas e seus uso como fungicidas
BRPI1011801A2 (pt) membranas biométricas e seus usos.
BRPI0906498A2 (pt) Anticorpo ron e seus usos
BRPI0816372A2 (pt) Ácidos 6-fenilnicotínicos substituídos e seu uso
BRPI0817234A2 (pt) Análogos de azacitidina e seus usos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2412 DE 28-03-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.